p53 Overexpression and steroid hormone receptor status in endometrial carcinoma

International Journal of Surgical Pathology

Volumn 8, Issue 3, 2000, Pages 213-222

  Fernando, S S E ^a   Wu, X ^a   Perera, L S ^a  

^a Senior Consultant Pathologist   (Australia)

Author keywords

Endometrial carcinoma; Estrogen receptor; Immunohistochemistry; p53; Progesterone receptor; pS2

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN PS2; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; TISSUE SECTION;

EID: 0033801580     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690000800309     Document Type: Article

References (35)

1. P53 function and dysfunction
2. Growth regulation of a cellular tumor antigen, p53, in nontransformed cells
3. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells
4. Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression
5. P53 interacts with p34cdc2 in mammalian cells: Implications for cell cycle control and oncogenesis
6. Overexpression and mutation of p53 in endometrial carcinoma
7. P53, guardian of the genome
8. Genetic mechanisms of tumor suppression by the human p53 gene
9. Tumor suppressor genes
10. P53 mutations in human cancers
11. Overexpression and mutation of p53 in epithelial ovarian cancer
12. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression
13. P53 mutations in human cancers
14. The p53 tumor suppressor gene
15. Posttranslational regulation of the 54kd cellular tumor antigen in normal and transformed cells
16. P53 expression in neoplasms of the uterine corpus
17. P53 gene mutations in human endometrial carcinoma
18. Overexpression and mutation of p53 in endometrial carcinoma
19. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus
20. Alterations of the p53 tumor suppressor gene and its association with activation of the c-k-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium
21. Immunohistochemical analysis of p53 protein overexpression in endometrial carcinomas: Inverse correlation with sex steroid receptor status
22. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival
23. Two pathogenetic types of endometrial carcinoma
24. Carcinoma of the endometrium: Analysis of 865 cases of adenocarcinoma and adenoacanthoma
25. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus
26. Clinicopathological characteristics of p53 overexpression in endometrial cancers
27. Prognostic significance of p53 overexpression in endometrial cancer
28. P53 Immunohistochemistry - A word of caution. Editorial
29. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
30. The prognostic importance of steroid receptors in endometrial carcinoma
31. Biochemical and immunohistochemical evaluation of estrogen and progesterone receptors in endometrial carcinoma and adenomatous hyperplasia: Correlations with stage, grade, and other clinicopathological features
32. Steroid hormone receptor content and lymph node status in endometrial cancer
33. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line
34. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB2
35. PS2 expression and response to hormonal therapy in patients with advanced breast cancer